In The Know-July 2026

July 2026
Pdf Summary
This July 2026 “Ed’s List” highlights a wide range of gynecologic oncology literature and related cross-disciplinary studies.<br /><br />Major themes include precision medicine, resistance mechanisms, survivorship, disparities, and health-system delivery. Several studies focus on hereditary cancer risk and BRCA testing, showing that lifetime breast and ovarian cancer risks vary substantially by BRCA result category and family history, and that even VUS or negative results may still confer elevated breast cancer risk. Other genomic studies examine ERBB2 amplification in endometrial cancer, noting enrichment in tumors from patients of African ancestry and supporting more comprehensive profiling.<br /><br />Therapeutic resistance and tumor biology are prominent. One study shows that acidic tumor microenvironments drive p300-mediated PARP inhibitor resistance in epithelial ovarian cancer, with p300 inhibition improving response. Another demonstrates that cisplatin-induced senescence-associated secretory phenotypes can promote ovarian cancer cell detachment and metastatic dissemination through metabolic reprogramming. In metastatic high-grade serous ovarian cancer, chemotherapy-induced IL1β-dependent neutrophil recruitment and NET formation were linked to chemoresistance, suggesting inflammatory pathways as potential targets.<br /><br />Clinical and comparative effectiveness studies address treatment choices and outcomes. Maintenance therapy remains an important strategy across gynecologic malignancies, especially with PARP inhibitors, VEGF inhibitors, and immunotherapy. In advanced cervical cancer treated with pembrolizumab plus chemotherapy, cisplatin and carboplatin appeared equivalent, while bevacizumab provided an early survival benefit. For early stage IA ovarian cancer, minimally invasive adnexectomy without capsule rupture did not worsen survival compared with open surgery. A phase II study also suggested promising activity for niraparib rechallenge plus bevacizumab in platinum-sensitive recurrent ovarian cancer.<br /><br />The issue also includes survivorship and prevention research. Interval salpingectomy with delayed oophorectomy was associated with less short-term sexual function decline than immediate risk-reducing salpingo-oophorectomy. Environmental epidemiology linked drinking water trihalomethanes to uterine cancer risk. Broader papers address genomic testing uptake in Medicare, disparities in ovarian cancer survival, AI-assisted radiotherapy for low-resource settings, and the need for stronger operational leadership in cancer service lines.
Keywords
gynecologic oncology
precision medicine
BRCA testing
PARP inhibitor resistance
endometrial cancer
ovarian cancer
cervical cancer
maintenance therapy
survivorship
health disparities